Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30301885.
- Also identified by DOI 10.1038/s41467-018-06366-z and PMC identifier 6178360.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37-57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs.
Medical subject headings
- Adrenocortical Carcinoma
- Genetic Heterogeneity
- Mutation Rate